2/4
07:00 am
maze
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Low
Report
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2/1
07:03 pm
maze
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock [Yahoo! Finance]
Medium
Report
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock [Yahoo! Finance]
1/28
10:12 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/25
03:05 am
maze
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at
Wall Street
Low
Report
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at
Wall Street
1/17
01:11 am
maze
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
1/16
12:28 pm
maze
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at BTIG Research from $37.00 to $46.00. They now have a "buy" rating on the stock.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at BTIG Research from $37.00 to $46.00. They now have a "buy" rating on the stock.
1/16
03:48 am
maze
Maze Therapeutics: An Innovative, Nature-Driven Platform [Seeking Alpha]
Low
Report
Maze Therapeutics: An Innovative, Nature-Driven Platform [Seeking Alpha]
1/9
07:16 am
maze
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% [Yahoo! Finance]
Medium
Report
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% [Yahoo! Finance]
1/5
07:13 am
maze
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
07:00 am
maze
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/22
06:55 am
maze
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth [Yahoo! Finance]
Low
Report
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth [Yahoo! Finance]
12/19
09:09 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/19
05:58 am
maze
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
12/13
01:11 am
maze
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at
Wall Street
Low
Report
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at
Wall Street
12/9
08:11 am
maze
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
12/4
07:03 am
maze
Maze Therapeutics (NASDAQ:MAZE) was given a new $55.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) was given a new $55.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.
12/3
10:09 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/25
09:46 am
maze
Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript [Seeking Alpha]
Low
Report
Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript [Seeking Alpha]
11/15
10:33 am
maze
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
11/15
01:42 am
maze
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
11/13
06:12 pm
maze
Maze Therapeutics (NASDAQ:MAZE) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.